SRP4596
IFN-alpha 1 human
recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
Manufacturer: Sigma Aldrich
Synonym(S): IFN-α 1, IFNA1, Interferon-α
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 100 μG | SRP4596-100-μG | In Stock | ₹ 39,205.20 |
SRP4596 - 100 μG
In Stock
Quantity
1
Base Price: ₹ 39,205.20
GST (18%): ₹ 7,056.936
Total Price: ₹ 46,262.136
biological source
human
recombinant
expressed in E. coli
Assay
≥95% (HPLC)≥95% (SDS-PAGE)
form
lyophilized
potency
1x10^8 units/mg
mol wt
~19.3 kDa
packaging
pkg of 100 μg
storage condition
avoid repeated freeze/thaw cycles
impurities
endotoxin, tested
NCBI accession no.
NM_024013
Related Products
Description
- General description: IFN-α1 (interferon α 1) is a type 1 interferon.[1] Human IFN-a1 is a 19.3kDa protein containing 166 amino acid residues. IFN-α1 belongs to the type I interferon (IFN) family and is present in leukocytes.[2] The IFN-α1 gene is mapped to human chromosome 9p21.3.[3]
- Application: IFN-alpha 1 human has been used: to treat Vero and breast cancer (MDA-MB-231) cells in interferon assay before viral infection[4] as a ligand to vaccinia virus B18R protein in analytical size exclusion chromatography[5]to treat chikungunya infected human embryonic kidney cell line (HEK293T) to test its effect on Signal transducer and activator of transcription 1 (STAT1) phosphorylation[6]as recombinant interferon to treat lung fibroblast cell line (IMR90) to monitor histone chaperone (HIRA) response[7]
- Biochem/physiol Actions: IFN-α1 (interferon α 1) is a lymphoid factor that possesses potent anti-viral activity.[8] IFN-α1 interacts with IFNAR1 (interferon α receptor 1) and IFNAR2. The interaction activates JAK1 (janus-activated kinase 1) and tyrosine kinase 2. These events phosphorylate and activate STAT1 and STAT2 (signal transducer and activator of transcription proteins), leading to the upregulation of interferon-stimulated genes some of which encode antiviral proteins.[9] IFN-alpha 1 (IFN-α1) mediates apoptosis in specific tissues. It may be useful in treating laryngeal carcinoma.[10] The interaction of microRNA, miR-181b with IFN-α1, is regarded as a risk factor in systemic lupus erythematosus.[11]
- Physical form: Lyophilized without any additives.
- Reconstitution: Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.
SAFETY INFORMATION
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Compare Similar Items
Show Difference
biological source: human
recombinant: expressed in E. coli
Assay: ≥95% (HPLC)≥95% (SDS-PAGE)
form: lyophilized
potency: 1x10^8 units/mg
mol wt: ~19.3 kDa
packaging: pkg of 100 μg
storage condition: avoid repeated freeze/thaw cycles
impurities: endotoxin, tested
NCBI accession no.: NM_024013
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥95% (HPLC)≥95% (SDS-PAGE)
form:
lyophilized
potency:
1x10^8 units/mg
mol wt:
~19.3 kDa
packaging:
pkg of 100 μg
storage condition:
avoid repeated freeze/thaw cycles
impurities:
endotoxin, tested
NCBI accession no.:
NM_024013
biological source: human
recombinant: expressed in E. coli
Assay: ≥90% (SDS-PAGE)
form: lyophilized
potency: __
mol wt: 15-16 kDa
packaging: pkg of 10 μg
storage condition: avoid repeated freeze/thaw cycles
impurities: endotoxin, tested
NCBI accession no.: Q6FH59
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥90% (SDS-PAGE)
form:
lyophilized
potency:
__
mol wt:
15-16 kDa
packaging:
pkg of 10 μg
storage condition:
avoid repeated freeze/thaw cycles
impurities:
endotoxin, tested
NCBI accession no.:
Q6FH59
biological source: human
recombinant: expressed in E. coli
Assay: ≥95% (SDS-PAGE)
form: lyophilized
potency: 0.5-4 μg/mL ED50 (determined by its ability to induce alkaline phosphatase production by ATDC-5 chondrogenic cells.)
mol wt: ~27 kDa
packaging: pkg of 50 μg
storage condition: avoid repeated freeze/thaw cycles
impurities: endotoxin, tested
NCBI accession no.: Q6KF10
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥95% (SDS-PAGE)
form:
lyophilized
potency:
0.5-4 μg/mL ED50 (determined by its ability to induce alkaline phosphatase production by ATDC-5 chondrogenic cells.)
mol wt:
~27 kDa
packaging:
pkg of 50 μg
storage condition:
avoid repeated freeze/thaw cycles
impurities:
endotoxin, tested
NCBI accession no.:
Q6KF10
biological source: human
recombinant: expressed in E. coli
Assay: ≥98% (HPLC)≥98% (SDS-PAGE)
form: lyophilized
potency: __
mol wt: ~15.4 kDa
packaging: pkg of 50 μg
storage condition: avoid repeated freeze/thaw cycles
impurities: endotoxin, tested
NCBI accession no.: P47929
biological source:
human
recombinant:
expressed in E. coli
Assay:
≥98% (HPLC)≥98% (SDS-PAGE)
form:
lyophilized
potency:
__
mol wt:
~15.4 kDa
packaging:
pkg of 50 μg
storage condition:
avoid repeated freeze/thaw cycles
impurities:
endotoxin, tested
NCBI accession no.:
P47929